MD Anderson Cancer Center

CPRIT Awards MD Anderson Over $29 million for Prevention Efforts, Cancer Research, and Faculty Recruitment

November 24th 2025

MD Anderson Cancer Center received more than $29 million from the Cancer Prevention and Research Institute of Texas to support prevention programs, research efforts, and faculty recruitment.

MD Anderson Experts Spotlight Key Immunotherapy Advances at 2025 SITC Annual Meeting

November 11th 2025

Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

Comprehensive Molecular Profiling of Renal Medullary Carcinoma Identifies TROP2 As a Promising Therapeutic Target

November 6th 2025

Researchers conducted the largest, most comprehensive molecular analysis of RMC, leading to the identification of TROP2 as a promising therapeutic target.

Allison Institute’s Third Annual Scientific Symposium Highlighted By Panel Discussion With Five Nobel Laureates

October 30th 2025

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its third annual scientific symposium on October 24.

Study Reveals How Bacteria in Tumors Drive Treatment Resistance in Cancer

October 21st 2025

MD Anderson and Phoenix SENOLYTIX Announce Strategic Cross-Licensing Agreement to Enhance Inducible Switch Technologies for Cell and Gene Therapies

September 19th 2025

The global cross-licensing agreement will facilitate work aimed at enhancing the development of inducible switch technologies for cell and gene therapies.

MD Anderson and Nature to Co-Host Conference on the Tumor Ecosystem

September 15th 2025

Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.

Novel Tool Helps Identify Key Targets to Strengthen CAR NK Cell Therapies

August 29th 2025

Researchers have developed the first genome-wide CRISPR screening tool for primary human natural killer cells.

Cancer-Associated Nerve Injury Leads to Chronic Inflammation and Immunotherapy Resistance

August 25th 2025

A study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation.

MD Anderson Ranked No. 1 in the Nation for Cancer Care

August 7th 2025

The MD Anderson Cancer Center was ranked number one in the nation for cancer care in U.S. News & World Report’s 2024-25 "Best Hospitals" survey.

MD Anderson and TOPPAN Holdings Announce Strategic Alliance to Co-Develop Organoid Technology for Evaluating Cancer Treatments

July 30th 2025

Collaboration will aim to obtain CAP/CLIA certification of organoid-based assay, followed by clinical studies in multiple indications

Most Patients With Advanced Melanoma Who Received Pre-Surgical Immunotherapy Remain Alive and Disease Free Four Years Later

July 11th 2025

Researchers found potential biomarkers that can highly predict which patients with stage III melanoma have better outcomes or are at high risk of recurrence.

Presurgical Radiation Therapy May Offer Alternative Approach to Treating Brain Metastases

June 27th 2025

Studies have suggested that pre-surgical SRT may be comparable to standard post-surgical SRT in patients with resectable brain metastases.

Researchers Identify Key B-Cell Lymphoma Traits Linked With Greatest Benefit From CD19 CAR T-Cell Therapy

June 18th 2025

MD Anderson researchers are enhancing CD19 CAR T-cell therapy outcomes in LBCL through precision medicine insights.

Researchers Identify Novel Target for High-Risk Multiple Myeloma

June 12th 2025

Researchers at MD Anderson Cancer Center have identified a novel target for high-risk multiple myeloma.

MD Anderson and HealthEx Announce Collaboration to Develop New Platform to Give Patients Direct Control of Data Access

June 9th 2025

ASCO: Pre-Surgical Combination Therapy Boosts Survival in Patients With Rare Thyroid Cancer

June 6th 2025

New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer

May 28th 2025

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.

CPRIT Awards over $21 Million to MD Anderson for Cancer Research and Faculty Recruitment

May 22nd 2025

CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment.

UT MD Anderson and Texas Children’s Hospital announce $150 Million Gift From Kinder Foundation to Launch Kinder Children’s Cancer Center

May 16th 2025

Historic donation unites two renowned institutions under one new world-class center created to end childhood cancer